Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH).

Puengel, Tobias; Tacke, Frank

Puengel, Tobias; Tacke, Frank.

Affiliation

Puengel T; Department of Hepatology & Gastroenterology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
Tacke F; Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Charitéplatz 1, Berlin 10117, Germany.

Expert Opin Investig Drugs ; 32(6): 451-461, 2023.

Article in En | MEDLINE | ID: mdl-37376813

Subject(s)
Key words

Efruxifermin (EFX, also AKR-001 or AMG876); Fibroblast growth factor 21 (FGF21); Non-alcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); liver cirrhosis; liver fibrosis

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Non-alcoholic Fatty Liver Disease Limits: Humans Language: En Journal: Expert Opin Investig Drugs Journal subject: TERAPIA POR MEDICAMENTOS Year: 2023 Document type: Article Affiliation country: Alemania

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google